The use of Aglepristone in the treatment of pregnancy related diabetic ketoacidosis: description of a case in a bitch

Gestational diabetes mellitus (GDM) is a rare disease in dogs that depends from an endogenous insulin supply that is insufficient to meet the tissues demands for the action of diabetogenic molecules like progesterone (P4), estradiol, growth hormone (GH), placental lactogen and placental cytokines. This report describes for the first time a case of GDM complicated by ketoacidosis treated with the P4 receptor blocker aglepristone. In our case aglepristone seemed to increase insulin sensitivity, helping in the resolution of ketoacidosis and of diabetes mellitus. Aglepristone may represent an effective and well tolerated therapeutic option in case of GDM.

Download Full-text

Growth Hormone-Binding Protein in Plasma Is Inversely Correlated to Placental Lactogen and Augmented with Increasing Body Mass Index in Healthy Pregnant Women and Women with Gestational Diabetes mellitus

Gynecologic and Obstetric Investigation ◽

10.1159/000292468 ◽

1994 ◽

Vol 38 (3) ◽

pp. 145-150 ◽

Cited By ~ 13

Author(s):

Marguerite Luthman ◽

Solveig Stock ◽

Sigbritt Werner ◽

Katarina Bremme

Keyword(s):

Diabetes Mellitus ◽

Body Mass Index ◽

Growth Hormone ◽

Gestational Diabetes ◽

Gestational Diabetes Mellitus ◽

Pregnant Women ◽

Placental Lactogen ◽

Hormone Binding ◽

Growth Hormone Binding Protein ◽

Hormone Binding Protein

Download Full-text

Metformin: A Drug of Choice for Gestational Diabetes Mellitus in Near Future- Hope or Despair?

Chattagram Maa-O-Shishu Hospital Medical College Journal ◽

10.3329/cmoshmcj.v14i2.25722 ◽

2015 ◽

Vol 14 (2) ◽

pp. 70-77

Author(s):

ASM Towhidul Alam ◽

Shaheda Ahmed

Keyword(s):

Diabetes Mellitus ◽

Insulin Sensitivity ◽

Gestational Diabetes ◽

Gestational Diabetes Mellitus ◽

Therapeutic Option ◽

Meta Analysis ◽

Drug Of Choice ◽

Oral Agents ◽

Oral Hypoglycaemic Drugs ◽

Near Future

Pregnancy is a potentially glucose intolerant condition. Insulin sensitivity decreases as the pregnancy advances. At the later stage of pregnancy, some women develop Gestational Diabetes Mellitus (GDM) particularly obese with pre-existing insulin resistance. Insulin is recognized as the gold standard for the treatment of GDM. However, difficulty in administration with multiple daily injections, potential for hypoglycemia, and increase in appetite and weight, make this therapeutic option troublesome for many pregnant patients. Oral hypoglycaemic drugs have been viewed with suspicion for many years in the management of women with diabetes during pregnancy or breastfeeding. However, recent data from well designed trials and meta-analysis may contribute a visible change in practice in terms of oral agents, especially metformin in gestational diabetes. Some cohort data are available and randomized trials are currently in progress to compare metformin with insulin. Evidence is emerging that metformin may improve insulin sensitivity during pregnancy. This may be beneficial in GDM. Use of metformin in pregnancy has opened a new horizon for GDM management. The aim of this article is to review the safety, efficacy and future of metformin in diabetic pregnancy, thus contributing meaningfully in safe motherhood.Chatt Maa Shi Hosp Med Coll J; Vol.14 (2); Jul 2015; Page 70-77

Download Full-text